Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12857/116060
DC FieldValueLanguage
dc.contributor.authorPierantoni, Francescoen
dc.contributor.authorMaruzzo, Marcoen
dc.contributor.authorBrunello, Antonellaen
dc.contributor.authorChiusole, Benedettaen
dc.contributor.authorPusole, Graziaen
dc.contributor.authorBezzon, Elisabettaen
dc.contributor.authorBasso, Umbertoen
dc.contributor.authorZagonel, Vittorinaen
dc.date.accessioned2020-03-15T17:34:18Z-
dc.date.available2020-03-15T17:34:18Z-
dc.date.issued2019en
dc.identifier.issn2234-943Xen
dc.identifier.urihttp://hdl.handle.net/20.500.12857/116060-
dc.description.abstractSoft tissue sarcomas are rare neoplasms, with a high mortality rate. Few drugs are available for the treatment of patients affected by metastatic sarcomas, who still have a 5-years survival rate lower than 20%. However, some of the more recent therapies can obtain long lasting responses in a portion of patients, such as Trabectedin. We analyzed four such cases treated at our Institute after progression to an anthracycline based regimen. In each case a therapeutic pause was proposed after at least 6 months of therapy with Trabectedin and in three out of four patients a re-challenge was proposed at progression, achieving again disease control or response. In two cases oligo-progressive sites were treated with localized therapies as stereotactic radiotherapy, delaying the systemic treatment re-start. In this article the reports of the patients involved are presented with a concise review of the relevant literature. Our findings support the favorable safety profile of Trabectedin and the feasibility of drug holidays, which should be at least discussed with the patient.en
dc.language.isoenen
dc.publisherFRONTIERS MEDIA SAen
dc.relation.ispartofFrontiers in oncologyen
dc.subjectTrabectedinen
dc.subjectdrug holidayen
dc.subjectmaintenance therapyen
dc.subjectre-challengeen
dc.subjectsoft-tissue sarcomaen
dc.titleTrabectedin Drug Holiday and Rechallenge in Soft Tissue Sarcomas: Report of 4 Cases and Literature Reviewen
dc.typeCase Reportsen
dc.identifier.doi10.3389/fonc.2019.00553en
dc.identifier.pmid31338321en
dc.identifier.isiWOS:000474722000001en
dc.relation.volume9en
dc.relation.firstpage553en
dc.source.typeReviewen
dc.publisher.placeAVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLANDen
dc.subject.keywordsplusRENAL-CELL CARCINOMAen
dc.subject.keywordsplusPHASE-IIen
dc.subject.keywordsplusANTITUMOR-ACTIVITYen
dc.subject.keywordsplusLIPOSARCOMAen
dc.subject.keywordsplusLEIOMYOSARCOMAen
dc.subject.keywordsplusPATIENTen
dc.contributor.affiliationMedical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy.en
dc.contributor.affiliationMedical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy.en
dc.contributor.affiliationMedical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy.en
dc.contributor.affiliationMedical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy.en
dc.contributor.affiliationMedical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy.en
dc.contributor.affiliationRadiology Unit, Department of Imaging and Medical Physics, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy.en
dc.contributor.affiliationMedical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy.en
dc.contributor.affiliationMedical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy.en
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairetypeCase Reports-
item.grantfulltextnone-
crisitem.author.deptISTITUTO ONCOLOGICO VENETO IOV IRCCS-
crisitem.author.deptISTITUTO ONCOLOGICO VENETO IOV IRCCS-
crisitem.author.deptISTITUTO ONCOLOGICO VENETO IOV IRCCS-
crisitem.author.deptISTITUTO ONCOLOGICO VENETO IOV IRCCS-
crisitem.author.deptISTITUTO ONCOLOGICO VENETO IOV IRCCS-
crisitem.author.orcid0000-0002-6256-9249-
crisitem.author.orcid0000-0003-2583-5226-
crisitem.author.orcid0000-0001-6449-6402-
crisitem.author.orcid0000-0002-5075-2177-
crisitem.author.orcid0000-0002-0829-2525-
Appears in Collections:Articles
Show simple item record

PubMed Central
Citations 50

3
Last Week
0
Last month
checked on Jan 4, 2022

WEB OF SCIENCETM
Citations

2
checked on Jun 27, 2022

Page view(s) 20

1
checked on Jun 30, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.